Aug 28, 2026
This podcast series delves into the evidence for oral micronutrient therapy in slowing the progression of age-related macular degeneration (AMD). In this episode, experts in the field discuss the evidence base for AMD-specific supplementation and key considerations for incorporating oral micronutrient therapy into AMD...
Aug 28, 2026
This podcast series delves into the evidence for oral micronutrient therapy in slowing the progression of age-related macular degeneration (AMD). In this episode, experts in the field discuss the emerging evidence for incorporation of B vitamins into AMD supplementation and implications for evolving oral micronutrient...
Aug 28, 2026
This podcast series delves into the evidence for oral micronutrient therapy in slowing the progression of age-related macular degeneration (AMD). In this episode, experts in the field discuss potential implications of expanded formulations of AMD supplements and interprofessional approaches for counseling patients.
To...
Aug 3, 2026
The treatment landscape for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO) continues to evolve, with ongoing efforts to improve durability and reduce treatment burden. Longer-acting second-generation anti-VEGF therapies,...
Jun 1, 2026
Second-generation anti-vascular endothelial growth factor (VEGF) therapies approved for the management of neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) continue to be evaluated in ongoing clinical and real-world studies. Findings from these...